IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients
Journal
Endocrine-Related Cancer
Journal Volume
22
Journal Issue
5
Pages
703-711
Date Issued
2015
Author(s)
Abstract
Aside from tumor cells, ovarian cancer-related ascites contains the immune components. The aim of this study was to evaluate whether a combination of clinical and immunological parameters can predict survival in patients with ovarian cancer. Ascites specimens and medical records from 144 ovarian cancer patients at our hospital were used as the derivation group to select target clinical and immunological factors to generate a risk-scoring system to predict patient survival. Eighty-two cases from another hospital were used as the validation group to evaluate this system. The surgical status and expression levels of interleukin 17a (IL17a) and IL21 in ascites were selected for the risk-scoring system in the derivation group. The areas under the receiver operating characteristic (AUROC) curves of the overall score for disease-free survival (DFS) of the ovarian cancer patients were 0.84 in the derivation group, 0.85 in the validation group, and 0.84 for all the patients. The AUROC curves of the overall score for overall survival (OS) of cases were 0.78 in the derivation group, 0.76 in the validation group, and 0.76 for all the studied patients. Good correlations between overall risk score and survival of the ovarian cancer patients were demonstrated by sub-grouping all participants into four groups (P for trend <0.001 for DFS and OS). Therefore, acombination of clinical and immunological parameters can provide a practical scoring system to predict the survival of patients with ovarian carcinoma. IL17a and IL21 can potentially be used as prognostic and therapeutic biomarkers.
SDGs
Other Subjects
gamma interferon; interleukin 10; interleukin 17; interleukin 17F; interleukin 21; interleukin 22; interleukin 23; interleukin 4; interleukin 6; tumor necrosis factor alpha; IL17A protein, human; interleukin 17; interleukin 21; interleukin derivative; tumor marker; adult; area under the curve; Article; ascites; cancer patient; cancer recurrence; cancer surgery; cancer survival; concentration (parameters); cytoreductive surgery; disease free survival; female; human; immunological parameters; major clinical study; medical record review; outcome assessment; ovary cancer; overall survival; prediction; protein expression; receiver operating characteristic; risk assessment; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; cancer grading; cancer staging; Cystadenocarcinoma, Serous; Endometrial Neoplasms; enzyme linked immunosorbent assay; follow up; metabolism; middle aged; mortality; Ovarian Neoplasms; pathology; prognosis; prospective study; survival rate; tumor recurrence; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Interleukin-17; Interleukins; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Prospective Studies; ROC Curve; Survival Rate
Publisher
BioScientifica Ltd.
Type
journal article